Skip to content
  • English
  • Business
  • Entertainment
  • National
  • Lifestyle
  • Education
Daily News India

Daily News India

Just another WordPress site

  • English
  • Business
  • Entertainment
  • National
  • Lifestyle
  • Education
  • Toggle search form
  • DHOOP CHHAON — A Heartwarming Tale of Love, Action & Emotions — Now Streaming on YouTube Entertainment
  • Giftex Is Back! It’s All Set to Enthrall Mumbai In August 2023 Business
  • Zarine Manchanda was Recently Appointed as the Coveted “Chairperson” Maharashtra Women Empowerment Business
  • Add-Shop E-Retail Ltd’s Rs. 48.90 crores Rights Issue to open on August 17 Business
  • 75,000 Native Trees Donated to Mark 75th Independence Day -Pune Organization Is Promoting Sustainable Lifestyle Lifestyle
  • Entrepreneur “Ansh Handa” achieves new heights of success in Digital Business A
  • Entrepreneurial Professionals Chander Sawhney, Deepika Vijay Sawhney, Inder Kalra team up to launch ‘Transique Corporate Advisors’ Business
  • Ezok Launches Its New Men’s Collection at Stelatoes Business

Chandan Healthcare Sharpens Focus on High-Margin Diagnostics Business Through Strategic Divestment

Posted on August 8, 2026 By

Lucknow (Uttar Pradesh) [India], August 8: Chandan Healthcare Limited (NSE – CHANDAN), one of the leading diagnostic and healthcare services providers, has announced the strategic divestment of its entire shareholding in Chandan Pharmacy Limited (“CPL”), reinforcing its focus on scaling its core, higher-margin diagnostics business.

The divestment aligns with Chandan Healthcare’s strategy to sharpen its focus on the higher-margin diagnostics business. The transaction will simplify the business structure and enable greater management and capital allocation towards expanding the Company’s core diagnostics operations.

Key Strategic Benefits

  • Improved Margin Profile: Deconsolidation of the lower-margin pharmacy business is expected to improve the overall business mix and enable the stronger profitability of diagnostics to reflect more clearly in the Company’s consolidated financial performance.
  • Sharper Focus on Core Diagnostics: Greater management bandwidth and resources can be directed towards expanding the diagnostics network, increasing capacity utilisation and scaling the Company’s core operations.
  • Capital Redeployment Towards Higher-Return Assets: Proceeds from the divestment are proposed to be deployed towards the development of new diagnostic centres and capacity expansion. This will enable the Company to reallocate capital from a lower-margin business towards higher-EBITDA opportunities.
  • Simplified Business Structure: A more focused diagnostics-led structure is expected to provide greater visibility into the scale, growth and profitability of the core business while enabling more relevant benchmarking with diagnostics-focused peers.

Transaction Details

The Board has approved the divestment of Chandan Healthcare’s entire 53.56% stake in Chandan Pharmacy Limited to Chandan Hospital Limited for a consideration of approximately ₹16.77 crore. The consideration is based on CPL’s independently determined total valuation of approximately ₹31.31 crore, following which CPL will cease to be a subsidiary of the Company.

Building a Focused Diagnostics Platform

Going forward, Chandan Healthcare intends to deploy greater financial and managerial resources towards expanding its diagnostics footprint, adding new centres, strengthening capacity and driving higher utilisation across its network.

The strategic realignment is expected to result in a simpler and more focused business structure, with a stronger margin profile and future growth increasingly driven by the scale-up of the Company’s core diagnostics operations.

About Chandan Healthcare Limited

Chandan Healthcare Limited, established in 2003, is one of India’s leading providers of diagnostic and pharmacy services and a key entity of the Chandan Group. The Company delivers a comprehensive range of pathology and radiology services through its expanding network across India.

As on June 30, 2026, the Company operates 327 diagnostic centres including 264 operational franchise centres, strengthening its presence across urban, semi-urban and emerging markets. Its diagnostic portfolio comprises more than 3,000 pathology tests and 500+ radiology tests, including blood tests, X-ray, ECG, Ultrasound, CT scan, MRI and several other specialized diagnostic investigations. The Company’s network includes NABL and NABH accredited pathology laboratories and radiology centres, reflecting its commitment to delivering reliable, high-quality diagnostic services.

Chandan Healthcare operates through a diversified business model comprising B2C (Retail Customers), B2B (Institutional & Corporate Clients) and B2G (Government PPP Contracts), providing a balanced and scalable revenue profile while catering to a wide spectrum of healthcare needs.

The Company was listed on the NSE Emerge platform on February 17, 2025. 

During FY26, the Company reported Total Income of ₹280.67 Cr, EBITDA of ₹56.84 Cr and Profit After Tax (PAT) of ₹27.06 Cr, reflecting its continued operational growth and financial strength.

If you object to the content of this press release, please notify us at pr.error.rectification@gmail.com. We will respond and rectify the situation within 24 hours.

Business Tags:Business

Post navigation

Previous Post: Intense Technologies Reports Q1 FY27 Results; Strengthens Growth with New Client Wins, AI-led Innovation and Global Expansion
Next Post: Paul Merchants Gets RBI Approval for Perpetual AD Category-II Licence Under Revised FEMA Framework

Related Posts

  • Patel Retail Limited Delivers Strong Q3 FY26 Performance with 36 Percent Revenue Growth and 96 Percent Surge in Profit Business
  • Maharashtra Govt reaffirms regulatory compliance for Laxmi Organic’s Lote facility Business
  • Jinkushal Industries Limited Announces Unaudited Financial Results for the Quarter Ended June 30, 2026 Business
  • AcreRise Named ‘Real Estate Developer of the Year’ at the Times Business Awards-2026 Business
  • Greeshma Nataraj’s Odyssey with GNCC: A Journey of Passion and Purpose: Business
  • Ducon Infratechnologies Approves Rights Issue of up to ₹25 Crore Business

Recent Posts

  • Gujarati Cinema Star Malhar Thakar Visited ‘Blue Club’ in Vadodara on October 25th
  • 27 Architecture Students of IPS Academy Undertake International Study Tour to Dubai and Abu Dhabi
  • Child Not Improving in Therapy? Why a Full Child Psychological Assessment Should Come First, as Indian-Origin Parents Abroad Seek Online Help
  • XLRI Jamshedpur Hosts KRONOS 2026, Exploring ‘Who Will Build the Company of Tomorrow?’
  • Ajwa Projects Limited IPO will open on October 28 and close on October 30, 2026

Recent Comments

  • Unknown on Participants Reap Rewards in Wellman’s 8-Week Digital Campaign: IPL Tickets, Autographed Virat Kohli Merchandise, and More!
  • Happy Pet, India’s First Pet Tech Company, Secures Strategic Funding from Dr. Devi Shetty Business
  • Hiraba no Khamkar Foundation Launches Lifelong Educational Assistance Scheme Education
  • This Republic Day, Founder Females of Vishwas Charitable Foundation Sunita, Vanitaa and Vibha shower their love for Asha School, Ahmedabad Business
  • Ozone Pharmaceuticals recently launched a new division AdLife; Currently in the inception stages Business
  • GIC Re to Host 29th FAIR Conference in Mumbai, 5–8 October 2025, Welcoming 700 Global Delegates Business
  • FlySBS Aviation Limited IPO Opens on August 01, 2025 Business
  • Filatex Fashions Ltd Board Approves 5-for-1 stock split Finance
  • Ishaan Aggarwal Leads Empire Cable Industries’ Next Phase of Growth and Global Expansion Lifestyle

Copyright © 2026 Daily News India.

Powered by PressBook News WordPress theme